Compare INTT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | ALXO |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.4M | 172.8M |
| IPO Year | 1997 | 2020 |
| Metric | INTT | ALXO |
|---|---|---|
| Price | $13.01 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $20.00 | $4.60 |
| AVG Volume (30 Days) | 114.0K | ★ 1.5M |
| Earning Date | 11-06-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $66,801,000.00 | N/A |
| Revenue This Year | $22.35 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $217.17 | ★ N/A |
| Revenue Growth | ★ 66.06 | N/A |
| 52 Week Low | $7.07 | $0.86 |
| 52 Week High | $20.00 | $2.66 |
| Indicator | INTT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 31.65 |
| Support Level | $12.71 | N/A |
| Resistance Level | $15.25 | $2.19 |
| Average True Range (ATR) | 0.82 | 0.13 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 41.92 | 24.79 |
inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.